Frazier Management’s Tempest Therapeutics TPST Stock Holding History

Frazier Management’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-7,162	Closed	-$7.37M	–	27
2020 Q1	$7.37M	Hold	7,162	–	–	0.84%	15
2019 Q4	$9.41M	Hold	7,162	–	–	1.58%	11
2019 Q3	$9.93M	Hold	7,162	–	–	3.1%	11
2019 Q2	$16.1M	Hold	7,162	–	–	4.14%	7
2019 Q1	$20.9M	Hold	7,162	–	–	5.04%	6
2018 Q4	$11.1M	Buy	+7,162	New	+$14.7M	2.86%	8

Other funds holding TPST

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Bpifrance Maisons Alfort, Cedex, France $1.36B AUM 21.86% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Frazier Management's TPST Position: Q2 2020 in Review

Frazier Management sold out of Tempest Therapeutics (TPST) in Q2 2020, closing a stake of 7,162 shares — an estimated $7.37M sold.

Frazier Management first reported a position in TPST in Q4 2018 and held it in 6 quarters. The position peaked at $20.9M in Q1 2019. 51 funds tracked by Wall St. Rank hold TPST as of Q2 2020.

Frazier Management reported no remaining Tempest Therapeutics position as of Q2 2020 after selling out during the quarter.
Frazier Management sold 7,162 Tempest Therapeutics shares in Q2 2020, an estimated $7.37M.
Frazier Management first reported a position in Tempest Therapeutics in Q4 2018 and held it in 6 quarters.
Frazier Management's Tempest Therapeutics position peaked at $20.9M in Q1 2019.
51 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2020.

Based on Frazier Management's 13F filing for Q2 2020, filed 4 Aug 2020.